Skip to content

Endovascular mechanical thrombectomy combined with umbilical cord blood mononuclear cell for acute intracranial large vessel occlusion: a randomized controlled clinical trial

Endovascular mechanical thrombectomy combined with umbilical cord blood mononuclear cell for acute intracranial large vessel occlusion: a randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048023
Enrollment
Unknown
Registered
2021-06-28
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Ischemic Stroke

Interventions

Test group:Intra-arterial injection of cord blood mononuclear cells before thrombectomy
Control group:Intra-arterial injection of saline before thrombectomy

Sponsors

Liaocheng People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnose AIS and present clinical symptoms and signs of acute ischemic stroke; 2. It is diagnosed as acute large vessels by imaging (lesions are in ICA, MCA-M1, MCA-M2); 3. Aged 35 to 70 years old; 4. Subjects or their guardians voluntarily sign informed consent; 5. NIHSS 2-25 points, mRS =6 points after admission, blood glucose 2.78 -22.2 mmol, INR =30x10^9/L.

Exclusion criteria

Exclusion criteria: 1. Before the onset of mRS score >=2, baseline NIHSS score 25; 2. CT or MRI examination of the head has the following evidence: significant space-occupying effect and midline shift. Intracranial tumors other than small meningiomas. Evidence of intracranial hemorrhage; 3. Severe head injury and residual neurological deficit within 90 days before the onset; 4. Suffer from neuropsychiatric diseases that may affect the evaluation of neurological function, such as dementia treated with cholinesterase inhibitors (such as donepezil); 5. Life expectancy 3; 7. Patients with co-infection, malignant tumors or hematological diseases.

Design outcomes

Primary

MeasureTime frame
90-day mRS score;

Secondary

MeasureTime frame
Serological indicators;Post-surgery 24h NIHSS score;Post-surgery 7d NIHSS score;TICI grade;Barthel Index;Median lesion volume on CT;Death;Asymptomatic intracranial hemorrhage;Symptomatic intracranial hemorrhage;Infarction in new territory at 5–7 days;Postoperative complications;

Countries

China

Contacts

Public ContactZhang Liyong

Liaocheng People's Hospital

13346256936@163.com+86 13346256936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026